Table 1 Clinicopathologic characteristics

Age(years)

64 (41–84)

64 (42–84)

64 (41–82)

0.908

Sex (Female/Male)

164 (23.7%)/529 (76.3%)

125 (25.7%)/362 (74.3%)

39 (18.9%)/167 (81.1%)

0.063

Smoke (1:Yes/ 0:No)

319 (46.3%)/370 (53.7%)

237 (48.7%)/250 (51.3%)

82 (23.7%)/120 (76.3%)

Missing 4 (1%)

0.054

Alcohol (1:Yes/ 0:No)

256 (37.2%)/432 (62.8%)

192 (39.4%)/295 (60.6%)

64 (31.8%)/137 (68.2%)

Missing 5 (2%)

0.069

Gastritis/Esophagitis (1:Yes/ 0:No)

22 (3.2%)/664 (96.8%)

13 (2.7%)/474 (97.3%)

9 (4.5%)/190 (95.5%)

Missing 7 (3%)

0.140

Diabetes (1:Yes/ 0:No)

41 (6%)/647 (94%)

27 (5.5%)/460 (94.5%)

14 (7%)/187 (93%)

Missing 5 (2%)

0.481

Tumor History (1:Yes/ 0:No)

17 (2.5%)/671 (97.5%)

13 (2.7%)/474 (97.3%)

14 (2%)/187 (98%)

Missing 5 (2%)

0.789

Family History Of Tumor (1:Yes/ 0:No)

75 (10.9%)/613 (89.1%)

60 (12.3%)/427 (87.7%)

15 (7.5%)/186 (92.5%)

Missing 5 (2%)

0.080

length of Tumor (cm)

3.36 (3.17–3.56)

3.37 (3.13–3.59)

3.36 (2.97–3.76)

0.996

Blood Type (A, B, AB, O)

214 (31.8%)/269 (40%) /0 (0%)/190 (28.2%)

138 (29.1%)/200 (42.1%) /0 (0%)/137 (28.8%)

Missing 12 (2%)

76 (38.4%)/69 (34.8%)/ 0 (0%)/53 (26.8%)

Missing 8 (4%)

0.077

Neutrophil(G) (1:> 3.3/0:< 3.3)10⁹/L

349 (50.8%)/338 (49.2%)

238 (49.5%)/243 (50.5%)

Missing 6 (1%)

111 (53.9%)/95 (46.1%)

0.318

Lymphocyte(G) (1:> 1.6/0:< 1.6)10⁹/L

349 (50.8%)/338 (49.2%)

239 (49.5%)/242 (50.3%)

Missing 6 (1%)

110 (53.4%)/96 (46.6%)

0.405

N/L(G) (1:> 1.5/0:< 1.5)

343 (50%)/343 (50%)

238 (49.6%)/242 (50.4%)

Missing 7 (1%)

105 (51%)/101 (49%)

0.830

Platelet(G) (1:> 187/0:< 187)10⁹/L

330 (48%)/357 (52%)

234 (48.6%)/247 (51.4%)

Missing 6 (1%)

96 (46.6%)/110 (53.4%)

0.677

N/P(G) (1:> 0.02/0:< 0.02)

350 (50.5%)/343 (49.5%)

242 (49.7%)/245 (50.3%)

108 (52.4%)/98 (47.6%)

0.561

ALP(G) (1:> 82/0:< 82)U/L

351 (51.2%)/334 (48.8%)

237 (49.5%)/242 (50.5%)

Missing 8 (2%)

114 (55.3%)/92 (44.7%)

0.182

APTT(G) (1:> 26.6/0:< 26.6) S

347 (50.7%)/337 (49.3%)

238 (49.7%)/241 (50.3%)

Missing 8 (2%)

109 (53.2%)/96 (46.8%)

Missing 1

0.453

CEA (ng/ml)

3.56 (2.01–5.10)

2.85 (2.65–3.04)

5.64 (0.44–11.72)

0.121

CYFRA211 (ng/ml)

2.44 (2.33–2.54)

2.41 (2.29–2.52)

2.52 (2.26–2.79)

0.361

NSE (ng/ml)

15.78 (15.34–16.22)

15.76 (15.24–16.28)

15.82 (15.00–16.64)

0.914

Pathology (Squamouscell/Neuroendocrine /Adenosquamous/Small cell/Adenocarcinoma/other)

651 (95.2%)/7 (1%)/7 (1%) /7 (1%)/4 (0.6%)/8 (1.2%)

453 (95%)/4 (0.8%)/5 (1%) /7 (1.5%)/4 (0.8%)/4 (0.8%)

Missing 10 (2%)

197 (95.6%)/3 (1.5%)/2 (1%) /0 (0%)/0 (0%)/4 (1.9%)

0.082

Grade (I/ I-II/ II/ II-III/ III)

32 (5%)/36 (5.6%)/240 (37.3%)/250 (38.9%) /85 (13.2%)

26 (5.7%)/26 (5.7%)/170 (37%)/178 (38.8%) /59 (12.9%)

Missing 28 (6%)

6 (3.3%)/10 (5.4%)/70 (38%) /72 (39.1%)/26 (14.1%)

Missing 22 (10%)

0.760

Concurrent Cancers (1:Yes/ 0:No)

49 (7.1%)/640 (92.9%)

36 (7.5%)/447 (92.5%)

Missing 4

13 (6.3%)/193 (93.7%)

0.746

Maximum Diameter Of Tumor (cm)

3.06 (2.94–3.18)

3.10 (2.96–3.25)

2.98 (2.77–3.19)

0.339

Depth of tumor invasion (cm)

3.33 (3.23–3.43)

3.38 (3.28–3.45)

3.21 (3.00–3.41)

0.096

Lymph-vascular Space invasion (1:Yes/ 0:No)

134 (19.5%)/554 (80.5%)

96 (19.9%)/386 (80.1%)

Missing 5

38 (18.4%)/168 (81.6%)

0.676

Neural invasion (1:Yes/ 0:No)

75 (89.1%)/612 (10.9%)

67 (13.9%)/414 (86.1%)

Missing 6

18 (8.7%)/188 (91.3%)

0.051